Genomic Profiling of HER2‐Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2‐Positive Advanced Gastric Cancer Treated with Trastuzumab
Conclusion.Our results provide for the first time a detailed molecular profile of concurrent genetic alterations in HER2‐positive AGC. PI3K pathway activation could be used as a predictive marker of worse outcome in this patient population. In addition, gains in copy number of other TKR genes in this subgroup may also influence the survival benefit obtained with trastuzumab.Implications for Practice.This article reports, for the first time, a detailed molecular profile of genomic alterations in patients with HER2‐positive advanced gastric cancer (AGC). PI3K/Akt/mTOR signaling pathway activation seems to have a differentially negative effect on overall survival and progression‐free survival in AGC treated with trastuzumab‐based chemotherapy. Combining different targeted agents could be a successful therapeutic strategy to improve the prognosis of HER2‐positive AGC.
Source: The Oncologist - Category: Cancer & Oncology Authors: Asuncion Diaz-Serrano, Barbara Angulo, Carolina Dominguez, Roberto Pazo-Cid, Antonieta Salud, Paula Jimenez-Fonseca, Ana Leon, Maria Carmen Galan, Maria Alsina, Fernando Rivera, J. Carlos Plaza, Luis Paz-Ares, Fernando Lopez-Rios, Carlos Gomez-Martin Tags: Gastrointestinal Cancer Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Gastric (Stomach) Cancer | Gastroenterology | Genetics | Herceptin | Study